Verition Fund Management
CTKB icon

Verition Fund Management’s Cytek Biosciences CTKB Stock Holding History

Verition Fund Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,452
Closed -$134K – 3672
2025
Q1 		$134K Buy
33,452
+19,810
+145% +$103K ﹤0.01% 3128
2024
Q4 		$88.5K Sell
13,642
-24,300
-64% -$145K ﹤0.01% 3088
2024
Q3 		$210K Buy
37,942
+24,185
+176% +$137K ﹤0.01% 2858
2024
Q2 		$76.8K Buy
+13,757
New +$82.6K ﹤0.01% 2761
2023
Q4 		– Sell
-30,451
Closed -$168K – 2394
2023
Q3 		$168K Buy
+30,451
New +$244K ﹤0.01% 2018
2023
Q2 		– Sell
-78,392
Closed -$720K – 2258
2023
Q1 		$720K Buy
+78,392
New +$843K 0.01% 1076

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Verition Fund Management's CTKB Position: Q2 2025 in Review

Verition Fund Management sold out of Cytek Biosciences (CTKB) in Q2 2025, closing a stake of 33,452 shares — an estimated $134K sold.

Verition Fund Management first reported a position in CTKB in Q1 2023 and held it in 6 quarters. The position peaked at $720K in Q1 2023. 158 funds tracked by Wall St. Rank hold CTKB as of Q2 2025.

  • Verition Fund Management reported no remaining Cytek Biosciences position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 33,452 Cytek Biosciences shares in Q2 2025, an estimated $134K.
  • Verition Fund Management first reported a position in Cytek Biosciences in Q1 2023 and held it in 6 quarters.
  • Verition Fund Management's Cytek Biosciences position peaked at $720K in Q1 2023.
  • 158 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.